Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 656 clinical trials
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)

In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.

  • 0 views
  • 29 Feb, 2024
  • 1 location
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 cohorts, Cohort1 and Cohort2.

  • 0 views
  • 19 Feb, 2024
Exercise and Tumor Blood Flow in Breast Cancer Patients

This research aims at investigating tumor blood flow response to acute exercise in human cancer patients. It is hypothesized and expected that acute exercise increases tumor blood flow, which could plausibly increase the efficacy of cancer treatment.

cancer treatment
  • 0 views
  • 19 Feb, 2024
Venetoclax SL-401 and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a …

ejection fraction
hydroxyurea
blastic plasmacytoid dendritic cell neoplasm
treatment regimen
interleukin-3
  • 0 views
  • 19 Feb, 2024
Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment

Gestational trophoblastic neoplasias (GTN) are characterized by the persistence of elevated hCG titers after complete uterine evacuation of a partial hydatidiform mole (PHM) or a complete hydatidiform mole.

  • 0 views
  • 19 Feb, 2024
Phase I Study in Advanced Malignancies

The doses of radiation administered in this study will be lower than those typically used to treat cancer. However, with administration of ALA, which has been shown to be selectively concentrated in neoplastic cells, it is reasonable to expect responses in the target lesion(s) with relative sparing of nearby normal …

photodynamic therapy
investigational therapies
mitomycin
major surgery
absolute neutrophil count
  • 0 views
  • 19 Feb, 2024
Quantifying Oxygen Utilization of Tumors Using Oxygen-Enhanced Molecular MRI

By using the oxygen-enhanced molecular MRI, researchers will be able to create spatial "maps" depicting areas of abnormal oxygen utilization unique to cancer. This type of information may be useful for diagnosing new cancers, understanding various "subtypes" of cancer that might utilize oxygen differently, or this information may be useful …

metastasis
brain metastasis
MRI
brain metastases
brain tumor
  • 0 views
  • 19 Feb, 2024
SBRT for Breast Cancer Oligometastases

Response and progression for these metastases will be evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions is used in the RECIST criteria.

breast neoplasm malignant female
positron emission tomography
bone metastases
sbrt
breast cancer
  • 0 views
  • 19 Feb, 2024
  • 0 views
  • 19 Feb, 2024
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy in subjects with advanced or metastatic solid tumors known to express HLA-G. This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor …

measurable disease
metastasis
solid tumour
hla-g
cancer
  • 0 views
  • 19 Feb, 2024